BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37833609)

  • 21. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgG anti-beta(2) glycoprotein I antibodies in Malaysian patients with antiphospholipid syndrome and systemic lupus erythematosus: prevalence and clinical correlations.
    Ong SG; Cheng HM; Soon SC; Goh E; Chow SK; Yeap SS
    Clin Rheumatol; 2002 Sep; 21(5):382-5. PubMed ID: 12223986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity.
    Akyüz Dağlı P; Erden A; Babaoğlu H; Karakaş Ö; Özdemir Ulusoy B; Konak HE; Armağan B; Erten Ş; Omma A
    Ir J Med Sci; 2024 Apr; 193(2):1099-1107. PubMed ID: 37737913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome.
    Meneghel L; Ruffatti A; Gavasso S; Tonello M; Mattia E; Spiezia L; Tormene D; Hoxha A; Fedrigo M; Simioni P
    Clin Chim Acta; 2015 Jun; 446():201-5. PubMed ID: 25935129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies to beta2-glycoprotein I: a potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus.
    Sanfilippo SS; Khamashta MA; Atsumi T; Amengual O; Bertolaccini ML; D'Cruz D; Amft N; Swana GT; Hughes GR
    J Rheumatol; 1998 Nov; 25(11):2131-4. PubMed ID: 9818654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extra-criteria antiphospholipid antibodies in patients with small vessel brain lesions and clinical manifestations associated with antiphospholipid syndrome.
    Estévez MÁ; Lanio N; Molina Á; Jiménez-León MR; Picado MJ; Esteban E; Sánchez S; Pallarés L; Julià MR
    J Stroke Cerebrovasc Dis; 2023 May; 32(5):107034. PubMed ID: 36842350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel enzyme immunoassay system for simultaneous detection of six subclasses of antiphospholipid antibodies for differential diagnosis of antiphospholipid syndrome.
    Nojima J; Motoki Y; Hara K; Sakata T; Ichihara K
    Blood Coagul Fibrinolysis; 2017 Jun; 28(4):316-322. PubMed ID: 27676644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients.
    Li S; Bai Y; Meng J; Wang Q; Tian X; Li M; Zeng X; Zhao J; Hu C
    Front Immunol; 2023; 14():1107510. PubMed ID: 37122726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China.
    Zhou Y; Hu C; Qi W; Long Y; Huang C; Wang Q; Tian X; Zhao J; Li M; Zeng X
    Lupus Sci Med; 2023 Aug; 10(2):. PubMed ID: 37607781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is There an Additional Value in Detecting Anticardiolipin and Anti-β2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?
    Chayoua W; Yin DM; Kelchtermans H; Moore GW; Gris JC; Musiał J; Zuily S; Ten Cate H; de Laat B; Devreese KMJ
    Thromb Haemost; 2020 Nov; 120(11):1557-1568. PubMed ID: 32696448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome.
    Pericleous C; Ferreira I; Borghi O; Pregnolato F; McDonnell T; Garza-Garcia A; Driscoll P; Pierangeli S; Isenberg D; Ioannou Y; Giles I; Meroni PL; Rahman A
    PLoS One; 2016; 11(6):e0156407. PubMed ID: 27253369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?
    Uludağ Ö; Çinar S; McDonnell T; Çene E; Yalçinkaya Y; Gül A; Inanç M; Artim Esen B
    Turk J Med Sci; 2023; 53(5):1067-1074. PubMed ID: 38813003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.
    Petrovas C; Vlachoyiannopoulos PG; Kordossis T; Moutsopoulos HM
    J Autoimmun; 1999 Nov; 13(3):347-55. PubMed ID: 10550222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus.
    Tebo AE; Willis R; Jaskowski TD; Guerra M; Pierangeli SS; Salmon J; Petri M; Branch DW
    Clin Chim Acta; 2016 Sep; 460():107-13. PubMed ID: 27346478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays.
    Chayoua W; Kelchtermans H; Moore GW; Musiał J; Wahl D; de Laat B; Devreese KMJ
    J Thromb Haemost; 2018 Oct; 16(10):2016-2023. PubMed ID: 30079628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome.
    Chayoua W; Kelchtermans H; Gris JC; Moore GW; Musiał J; Wahl D; de Groot PG; de Laat B; Devreese KMJ
    J Thromb Haemost; 2020 Jan; 18(1):169-179. PubMed ID: 31519058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
    Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
    Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome.
    Shi H; Zheng H; Yin YF; Hu QY; Teng JL; Sun Y; Liu HL; Cheng XB; Ye JN; Su YT; Wu XY; Zhou JF; Norman GL; Gong HY; Shi XM; Peng YB; Wang XF; Yang CD
    Clin Chem Lab Med; 2018 Mar; 56(4):614-624. PubMed ID: 29166262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) increase the risk for thrombosis based on lupus anticoagulant positivity.
    Zhang Y; Su Y; Guo H; Wang L; Li A; Wang C; Zhang J; Qiao R
    Clin Biochem; 2023 Feb; 112():17-23. PubMed ID: 36535385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.